The total prevalent population of Sarcopenia in 7MM was 33,321,576 in 2017. The total prevalent cases of Sarcopenia in the United States was found to be 749,154 in 2017. The prevalence of Sarcopenia by gender in the US in 2017 was 9,932,700 Males and 7,867,838 Females.
In 2017, the therapeutic market of Sarcopenia in 7MM was USD 1166.26 Million.
Better insights into disease intervention, increase in research initiatives, need for cost effective therapy are some of the key factors expected to drive the Sarcopenia market forward in the coming years.
Some of the key companies in the Sarcopenia market include Biophytis, Novartis, Amazentis, Eli Lilly and Company, Regeneron Pharmaceuticals, Sanofi, Immunoforge and many others.
For more information on Sarcopenia market visit:
https://www.delveinsight.com/report-store/sarcopenia-market